000149050 001__ 149050
000149050 005__ 20250923084443.0
000149050 0247_ $$2doi$$a10.3389/fendo.2024.1450573
000149050 0248_ $$2sideral$$a142154
000149050 037__ $$aART-2024-142154
000149050 041__ $$aeng
000149050 100__ $$0(orcid)0000-0002-2865-5813$$aArriba, Antonio de$$uUniversidad de Zaragoza
000149050 245__ $$aUse of connected injection device has a positive effect on catch-up growth in patients with growth disorders treated with growth hormone therapy
000149050 260__ $$c2024
000149050 5060_ $$aAccess copy available to the general public$$fUnrestricted
000149050 5203_ $$aIntroductionHuman growth hormone (hGH) therapy in children can be administered by subcutaneous injection using either a manual non-connected device, which is a portable injection pen loaded with a pre-filled cartridge, or an electronic connected device. The electronic device is connected to a platform where adherence data is recorded and available for health care professionals (HCPs) and patient support programs. Real-world data used in the clinic, includes regular monitoring of adherence data which are shared with families during patients’ visits and aim to determine the root causes of poor adherence. This study aimed to identify whether there are differences in growth during the first four years of treatment depending on the device, i.e. non-connected versus connected devices.MethodsThis retrospective study reports treatment of either GH deficiency or short stature secondary to birth size small for gestational age (SGA) in 174 pediatric patients attending Miguel Servet Hospital, Zaragoza, Spain. hGH treatment was administered with manual non-connected devices in 87 patients and 87 patients used connected devices. Height was followed for 4 years after start of hGH therapy.ResultsIn total, 57% of subjects had GHD and 43% were SGA. Height standard deviation score (HSDS) at treatment start was higher (p<0.001) in the non-connected device group compared to the connected device group. Change of HSDS in the connected device group was significantly higher in the second (+0.13), third (+0.20) and fourth (+0.23) year of treatment compared to the non-connected group after adjustment for age and HSDS at treatment start, sex, indication, dose and Tanner stages during treatment, and timing of measurements.DiscussionThese results support the use of the connected device for hGH treatment of pediatric growth disorders.
000149050 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000149050 590__ $$a4.6$$b2024
000149050 592__ $$a1.472$$b2024
000149050 591__ $$aENDOCRINOLOGY & METABOLISM$$b43 / 191 = 0.225$$c2024$$dQ1$$eT1
000149050 593__ $$aEndocrinology, Diabetes and Metabolism$$c2024$$dQ1
000149050 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000149050 700__ $$avan Dommelen, Paula
000149050 700__ $$aSavage, Martin O.
000149050 7102_ $$11011$$2670$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Pediatría
000149050 773__ $$g15 (2024), 1-6$$pFront. endocrinol.$$tFrontiers in Endocrinology$$x1664-2392
000149050 8564_ $$s438130$$uhttps://zaguan.unizar.es/record/149050/files/texto_completo.pdf$$yVersión publicada
000149050 8564_ $$s2058724$$uhttps://zaguan.unizar.es/record/149050/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000149050 909CO $$ooai:zaguan.unizar.es:149050$$particulos$$pdriver
000149050 951__ $$a2025-09-22-14:52:13
000149050 980__ $$aARTICLE